The National HBPA or Horseman’s Benevolent and Protective Association recently announced an opposition to Horseracing Integrity Act (S. 1820) which was the official Senate version introduced in the past week by Martha McSally (R-AZ) and Sens. Kirsten Gillibrand (D-NY).
Representing the horse trainers and owners of the thoroughbred racehorses, the HBPA showed stringent commitment for its opposition to the latest House Companion move introduced just earlier in the year by Representatives Andy Barr (R-KY-06) (H.R. 1754) and Paul Tonko (D-NY-20). Eric Hamelback, HBPA CEO mentioned that Senator McSally and Senator Gillibrand have both been clearly misguided. Banning the Lasix for race days would lead to more deaths for the equine. Additionally, the added regulations will lead to several jobs being lost.
The HBPA is in complete support of the local veterinary community as well as the science upon which their opinions are based. Under the S.1820, trainers, owners, as well as veterinarians shall no longer possess the choice of the utilization of the therapeutic and legal medication known as Furosemide which is more commonly termed as Lasix. This particular medication is used for horses to bring down the instances of EIPH or Exercise Induced Pulmonary Hemorrhages. When unchecked, the EIPH can also lead to bleeding. This drug has been used with adherence to the standard rules and regulations while maintaining safety standards for more than 40 years in the horse racing sector of America.
Horses participating in races often tend to experience episodes of EIPH during intense sessions of hardcore exercise. Current policy opted by the horse racing industry endorses as well as strictly regulates the use of the drug on the day of the race. This is in order to promote better health as well as the welfare of the affected horse during the race. Hamelback also mentioned that a complete ban of Lasix will lead to an increased number of on-track fatality. While the investigators are committed to locating answers that can easily prevent this issue, a new bill completely banning the use of this drug isn’t the right answer.
Moreover, HBPA possesses deep concerns with regards to the additional costs and fees that the bill S.1820 shall place upon the horse racing sector. For smaller business owners, these latest fees shall be the point where they might move away from the business. The wealthy business owners might not be affected with this added expense, the jobs in rural or agrarian areas shall be lost with lives devastated.